| Expression pattern: |
UP |
| Associated gene: |
PARP9, PRKCI, CCND1, CDK6, Bcl-2, Bax, C-casp3, Ago2 |
| Associated microRNA: |
miR-186-5p |
| Biological function: |
circPRKCI promotes EC cell viability, colony formation, cell cycle progression, tumor growth, and radioresistance; circPRKCI silencing represses tumor growth and increases radiosensitivity and apoptosis after radiation. |
| Molecular mechanism: |
circPRKCI functions as a ceRNA by sponging miR-186-5p to regulate PARP9 expression, thereby modulating EC malignancy and radioresistance. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (promotes); cell cycle (promotes); apoptosis (inhibits); radioresistance (promotes); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Actinomycin D / DRB Stability Assay; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Western Blot; In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
circPRKCI might be a potential target for improving the prognosis of EC patients. |
| Description: |
circPRKCI is upregulated in esophageal cancer tissues and cells. It acts as an oncogenic circRNA that promotes EC cell viability, colony formation, cell cycle progression, tumor growth, and radioresistance. Mechanistically, circPRKCI sponges miR-186-5p to increase PARP9 expression, and its silencing suppresses EC progression and enhances radiosensitivity. |
| Confidence score: |
0.7595 |